We are looking for a motivated PhD student for exciting spatial transcriptomics projects in urothelial cancer! Our lab has been involved in important clinical and translational molecular UC research in the past years. PM if you are interested to join! xing.com/jobs/erlangen-…

MODERN is now activated. Please help define a precision-based approach to adjuvant therapy in bladder cancer. Bladder Cancer Advocacy Network Uromigos Alliance for Clinical Trials in Oncology Alan Tan Stephanie Berg Jonathan Rosenberg MD Shilpa Gupta Andrea Apolo, M.D. SWOG Cancer Research Network ECOG-ACRIN Cancer Research Group Petros Grivas Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO DrTylerStewart

Updated analysis showing ctDNA as potentially predictive and prognostic marker after cystectomy in muscle invasive bladder cancer. CtDNA clearance also looks important. New data on relapse rates in ctDNA-ve with be #EAU24 joaquim bellmunt European Urology

Big news for our #melanoma community today: lifileucel is finally FDA approved! I think this is a paradigm shifting, "first-of-many" approval in the field of cellular therapeutics for solid tumors. Much more to do, but for today, we celebrate! ir.iovance.com/news-releases/…

A glorious end to Thursday in Chicago. This evening's sunset. #weather #ilwx #news #chicago

🚨Call for Abstracts! You can secure a sponsored seat at #KCRS24 by sharing your work: ➡️Basic/Translational Research ➡️Clinical Research ➡️Trials in Progress Details: bit.ly/KCRS24Abstract… Submit by May 6. Don't miss your chance! OncoAlert

The UChicago Breast Cancer Program is excited organize a Stat of the Science Summit on March 21, 2024 in downtown Chicago. Please join us! #bcsm

Thrilled on our lastest publication in European Urology Oncology! ctDNA may revolutionize the way we choose treatment modalities for patients with bladder cancer. Paving our way in adding the letter G-for genomic to TNM staging, adding another layer of clarity to our patients.

Excited to welcome those in the Chicago area to the next GU Rounds Ivy Room Chicago! Jam packed agenda +dinner w/ exciting cross-disciplinary discussions in prostate, bladder, renal cancers. Still a few spots left to sign up @ gurounds.com for this April 3 CME event

I’m thrilled to announce that National Cancer Institute renewed our designation as a Comprehensive Cancer Center for the high-impact work we do for cancer patients and the community. ow.ly/HUOc50R5Jut #NothingWillStopUs #WeAreNCIDesignated #UChiCancer50 Kunle Odunsi, MD

Spring is Stunning in Chicago.

Updated data with lenvatinib and Pembrolizumab in 158 1st line advanced non-clear cell renal cancer #ikcs24. 8 mnths extra FU. RR= 50% seems higher than sunitinib. 18 month mPFS and 80% 12 month OS also looks ⬆️, but randomised trials such as SAMETA and XL92/nivo remain important

FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer. fda.gov/drugs/resource… #OCENewsBurst

Join me for this social learning CME online activity. We review the rapidly changing landscape of bladder cancer - it's mostly self-paced and will be fun! New Perspectives in the Front-line Treatment of Metastatic Bladder Cancer medicallogix.gathered.com/invitation?ref…

The Faltas lab is seeking postdoctoral candidates. Details and contact information below. Please spread the word and retweet.

AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or observation for 1 year. The pembrolizumab group had a median disease-free survival twice as long as the observation group. nej.md/4gh1b9D #ESMO24

🎯AMBASSADOR trial remains positive in extended follow-up data (45m). Pembrolizumab doubled DFS vs placebo. The OS data is still immature. Amazing presentation by Andrea Apolo, M.D. OncoAlert ESMO - Eur. Oncology IntraMed Oncología

Dr Apolo Andrea Apolo, M.D. our study chair and bladder cadre leader was center stage to present A031501/AMBASSADOR +DFS and our publication in NEJM This Truly takes a Village! ESMO - Eur. Oncology Alliance for Clinical Trials in Oncology NCICancerTrials Merck SWOG Cancer Research Network ECOG-ACRIN Cancer Research Group #ESMO24 OncoAlert